Eli Lilly antibody drug fails in a COVID-19 study; others go on

Independent monitors had paused enrolment in the study two weeks ago because of a possible safety issue. But on Monday, the National Institute of Allergy and Infectious Diseases, which sponsors the study, said a closer look found no safety problem but a low chance that the drug would prove helpful for hospitalized patients.

from News-Economic Times https://ift.tt/2G0ZGA4